{"id":31317,"date":"2014-09-17T07:24:04","date_gmt":"2014-09-17T11:24:04","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=31317"},"modified":"2014-09-17T07:24:04","modified_gmt":"2014-09-17T11:24:04","slug":"boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317","title":{"rendered":"Boston Scientific Corporation (NYSE:BSX)\u2019s REPRISE II Clinical Data Demonstrates Effectiveness And Safety Of Lotus\u2122 Valve System"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/17\/2014 (wallstreetpr) \u2013 The clinical trial of <a href=\"http:\/\/finance.yahoo.com\/news\/reprise-ii-data-demonstrate-sustained-200500242.html\" target=\"_blank\"><strong>Lotus\u2122 Valve System<\/strong><\/a> of <strong>Boston Scientific Corporation (NYSE:BSX)<\/strong> is enduringly proving its performance in terms of being the less persistent treatment for aortic stenosis patients. The company released new data, according to which the performance is demonstrated to be strong for patients who are at high possibility for the treatment involving surgical valve replacement.<\/p>\n<p style=\"text-align: justify;\"><strong>Vital Facts of the Data<\/strong><\/p>\n<p style=\"text-align: justify;\">The clinical trial called REPRISE II has been confirmed as a safe and effective one with over 86% patients showing signs of complete lack of leaking or paravalvular aortic regurgitation. Also none of the patients demonstrated moderate or severe aforesaid condition.<\/p>\n<p style=\"text-align: justify;\">At the 26th Transcatheter Cardiovascular Therapeutics meeting, the data from REPRISE I and REPRISE II studies were presented. While REPRISE I clinical trial has already come out with the results, the latter one is still going on by the way of multi-center and single-arm study. The motive behind undertaking REPRISE II studies is to evaluate the performance as well as safety aspects of Lotus Valve System among patients suffering from rigorous calcific aortic stenosis. These patients are considered as the ones at risk for valve replacement through surgical processes.<\/p>\n<p style=\"text-align: justify;\">In the study, 120 patients were involved at 14 different locations situated at the U.K., France, Germany and Australia.<\/p>\n<p style=\"text-align: justify;\"><strong>What Experts Say?<\/strong><\/p>\n<p style=\"text-align: justify;\">The MonashHeart Director at Melbourne-based Monash Medical Centre, <em>Professor Ian Meredith<\/em> says that the data from REPRISE II demonstrated sustained and strong clinical benefits. He added that the results explained about bringing down the rate of cardiovascular mortality and paravalvular regurgitation, along with the brilliance in terms of hemodynamics.<\/p>\n<p style=\"text-align: justify;\">The characteristics, as well as advantages of the Lotus Valve System, have been cemented by way of positive clinical data. The system shall now be able to offer ability of achieving primary valve placement with precision because of being loaded with the latest technology.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/17\/2014 (wallstreetpr) \u2013 The clinical trial of Lotus\u2122 Valve System of Boston Scientific Corporation (NYSE:BSX) is enduringly proving its performance in terms of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":25594,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236,264],"tags":[2960,8954,1020],"stock_ticker":[],"class_list":["post-31317","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-health","tag-boston-scientific-corporation-nysebsx","tag-ian-meredith","tag-nysebsx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Boston Scientific Corporation (NYSE:BSX)\u2019s REPRISE II Clinical Data Demonstrates Effectiveness And Safety Of Lotus\u2122 Valve System - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boston Scientific Corporation (NYSE:BSX)\u2019s REPRISE II Clinical Data Demonstrates Effectiveness And Safety Of Lotus\u2122 Valve System - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/17\/2014 (wallstreetpr) \u2013 The clinical trial of Lotus\u2122 Valve System of Boston Scientific Corporation (NYSE:BSX) is enduringly proving its performance in terms of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-17T11:24:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"352\" \/>\n\t<meta property=\"og:image:height\" content=\"143\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Boston Scientific Corporation (NYSE:BSX)\u2019s REPRISE II Clinical Data Demonstrates Effectiveness And Safety Of Lotus\u2122 Valve System\",\"datePublished\":\"2014-09-17T11:24:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317\"},\"wordCount\":328,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg\",\"keywords\":[\"Boston Scientific Corporation (NYSE:BSX)\",\"Ian Meredith\",\"NYSE:BSX\"],\"articleSection\":[\"Business\",\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317\",\"name\":\"Boston Scientific Corporation (NYSE:BSX)\u2019s REPRISE II Clinical Data Demonstrates Effectiveness And Safety Of Lotus\u2122 Valve System - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg\",\"datePublished\":\"2014-09-17T11:24:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg\",\"width\":352,\"height\":143},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boston Scientific Corporation (NYSE:BSX)\u2019s REPRISE II Clinical Data Demonstrates Effectiveness And Safety Of Lotus\u2122 Valve System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Boston Scientific Corporation (NYSE:BSX)\u2019s REPRISE II Clinical Data Demonstrates Effectiveness And Safety Of Lotus\u2122 Valve System - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317","og_locale":"en_US","og_type":"article","og_title":"Boston Scientific Corporation (NYSE:BSX)\u2019s REPRISE II Clinical Data Demonstrates Effectiveness And Safety Of Lotus\u2122 Valve System - Wall Street PR","og_description":"Boston, MA 09\/17\/2014 (wallstreetpr) \u2013 The clinical trial of Lotus\u2122 Valve System of Boston Scientific Corporation (NYSE:BSX) is enduringly proving its performance in terms of [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-17T11:24:04+00:00","og_image":[{"width":352,"height":143,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Boston Scientific Corporation (NYSE:BSX)\u2019s REPRISE II Clinical Data Demonstrates Effectiveness And Safety Of Lotus\u2122 Valve System","datePublished":"2014-09-17T11:24:04+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317"},"wordCount":328,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg","keywords":["Boston Scientific Corporation (NYSE:BSX)","Ian Meredith","NYSE:BSX"],"articleSection":["Business","Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317","url":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317","name":"Boston Scientific Corporation (NYSE:BSX)\u2019s REPRISE II Clinical Data Demonstrates Effectiveness And Safety Of Lotus\u2122 Valve System - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg","datePublished":"2014-09-17T11:24:04+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg","width":352,"height":143},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/boston-scientific-corporation-nysebsxs-reprise-ii-clinical-data-demonstrates-effectiveness-and-safety-of-lotus-valve-system-31317#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Boston Scientific Corporation (NYSE:BSX)\u2019s REPRISE II Clinical Data Demonstrates Effectiveness And Safety Of Lotus\u2122 Valve System"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=31317"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31317\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/25594"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=31317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=31317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=31317"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=31317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}